(-0.28%) 4 997.15 points
(0.47%) 37 951 points
(-1.00%) 15 446 points
(0.60%) $83.23
(2.33%) $1.798
(0.16%) $2 401.80
(0.56%) $28.54
(-1.26%) $942.50
(-0.24%) $0.937
(-0.42%) $10.99
(-0.05%) $0.804
(-0.71%) $93.23
Live Chart Being Loaded With Signals
Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases...
Stats | |
---|---|
今日成交量 | 1.91M |
平均成交量 | 954 093 |
市值 | 6.57B |
EPS | $0 ( 2024-02-22 ) |
下一个收益日期 | ( $0 ) 2024-05-08 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -66.29 |
ATR14 | $1.830 (1.06%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-09-26 | Desai Antal Rohit | Sell | 134 | Class A common stock |
2023-09-26 | Desai Antal Rohit | Sell | 993 929 | Class B common stock |
2023-09-26 | Mcgaughy R Kent Jr | Sell | 280 | Class A common stock |
2023-09-26 | Mcgaughy R Kent Jr | Sell | 278 309 | Class B common stock |
2023-09-26 | Mcgaughy R Kent Jr | Sell | 699 | Stock Option (right to buy) |
INSIDER POWER |
---|
-100.00 |
Last 100 transactions |
Buy: 0 | Sell: 4 695 639 |
音量 相关性
Reata Pharmaceuticals Inc 相关性 - 货币/商品
Reata Pharmaceuticals Inc 财务报表
Annual | 2022 |
营收: | $2.22M |
毛利润: | $2.22M (100.00 %) |
EPS: | $-8.59 |
Q2 | 2023 |
营收: | $22.75M |
毛利润: | $21.90M (96.28 %) |
EPS: | $5.12 |
Q1 | 2023 |
营收: | $195 000 |
毛利润: | $195 000 (100.00 %) |
EPS: | $-3.00 |
Q4 | 2022 |
营收: | $914 000 |
毛利润: | $914 000 (100.00 %) |
EPS: | $-2.35 |
Financial Reports:
No articles found.
Reata Pharmaceuticals Inc
Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases. The company is developing Phase 3 clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney disease (CKD) caused by Alport syndrome, as well as for a form of pulmonary arterial hypertension associated with connective tissue disease; omaveloxolone that is Phase II clinical trial to treat Friedreich's ataxia; and conduct Phase 2 study for various form of CKD, such as IgA nephropathy, type 1 and type 2 diabetic CKD, hypertensive CKD, focal segmental glomerulosclerosis, and others. It is also developing RTA 901 for neurological diseases; and RTA 1701 for the potential treatment of a range of autoimmune, inflammatory, and fibrotic diseases. In addition, the company offers bardoxolone for the treatment of autosomal dominant polycystic kidney disease. Further, it has a strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize bardoxolone for renal, cardiovascular, diabetes, and various other related metabolic indications in Japan, China, Hong Kong, Macao, South Korea, Taiwan, Thailand, Singapore, the Philippines, Malaysia, Indonesia, Brunei, Vietnam, Laos, Myanmar, and Cambodia; and AbbVie Inc. to jointly research, develop, and commercialize all second- and later-generation Nrf2 activators for all indications other than renal, cardiovascular, and metabolic indications. The company was formerly known as Reata Discovery, Inc. and changed its name to Reata Pharmaceuticals, Inc. in May 2005. Reata Pharmaceuticals, Inc. was incorporated in 2002 and is headquartered in Plano, Texas.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。